The histamine H 3 receptor, a novel histamine receptor subtype, has been identified in rat brain cortical slices and shown to inhibit histamine release 1, 2) in the brain and several peripheral tissues.
perior mesenteric artery was cannulated and flushed gently with Krebs-Ringer bicarbonate solution (Krebs solution) to eliminate blood from the vascular bed. After removal of the entire intestine and associated vascular bed, the mesenteric vascular bed was separated from the intestine by cutting close to the intestinal wall. Only the four main arterial branches from the superior mesenteric trunk running to the terminal ileum were perfused. All other branches of the superior mesenteric artery were tied off. The isolated mesenteric vascular bed was placed in a water-jacketed organ bath maintained at 37°C, perfused with a modified (see below) Krebs solution at a constant flow rate of 5 ml/min with a peristaltic pump (model AC-2120, ATTO, Tokyo, Japan) and superfused with the same solution at a rate of 0.5 ml/min to prevent drying. The Krebs solution was bubbled with a mixture of 95% O 2 -5% CO 2 before passage through a warming coil maintained at 37°C. The modified Krebs solution was of the following composition (mM): NaCl 119.0, KCl 4.7, CaCl 2 2.4, MgSO 4 1.2, NaHCO 3 25.0, KH 2 PO 4 1.2, disodium ethylenediaminetetraacetic acid (EDTA) 0.03 and dextrose 11.1 (pH 7.4). Changes in the perfusion pressure were measured with a pressure transducer (model TP-400T, Nihon Kohden, Tokyo, Japan) and recorded using a pen recorder (model U-228, Nippon Denshi Kagaku, Tokyo, Japan).
Chemical Removal of Vascular Endothelium
To remove the vascular endothelium, preparations with resting tone were perfused with a 1.80 mg/ml solution of sodium deoxycholate (Sigma Aldrich Japan Co., Tokyo, Japan) in saline for 30 s. This caused a transient increase (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) in perfusion pressure. Then, the preparations were rinsed with sodium deoxycholate-free Krebs solution for 40 min. After the preparations were contracted by perfusion with Krebs solution containing methoxamine (a selective a 1 -adrenoceptor agonist, 2 mM, Nihon Shinyaku, Kyoto, Japan), chemical removal of the endothelium was assessed by the lack of a relaxant effect induced by a bolus injection of 1 nmol acetylcholine (Daiichi Pharmaceutical, Tokyo, Japan), which was injected directly into the perfusate proximal to the arterial cannula with an injection pump (model 975, Harvard Apparatus, Holliston, MA, U.S.A.). Volume was 100 ml for 12 s.
Experimental Protocols Isolated mesenteric vascular beds with intact endothelium were perfused with Krebs solution and the perfusion pressure was increased by continuous perfusion of methoxamine (7 mM). After the elevated perfusion pressure stabilized, Krebs solution containing methoxamine and a-methylhistamine (Sigma Aldrich) at a concentration of 1, 3, 10, 30 or 100 mM was perfused for 1 min. To assess the mechanism underlying the vascular effect, amethylhistamine perfusion was carried out during perfusion of Krebs solution containing methoxamine and a histamine H 3 receptor antagonist thioperamide (1 mM, Sigma Aldrich) (pA 2 ϭ8.96)
2) or clobenpropit (1 mM, Sigma Aldrich) (pA 2 ϭ 10.10), 6) a histamine H 1 receptor antagonist (chlorpheniramine; 1 mM, Sigma Aldrich) (pA 2 ϭ8.25) 25) or a histamine H 2 receptor antagonist (cimetidine; 1 mM, Sigma Aldrich) (pA 2 ϭ6.65). 25) Each antagonist was pretreated for 30 min before the first perfusion of a-methylhistamine.
To assess the influence of the endothelium, the a-methylhistamine-induced vascular responses were examined in preparations denuded with sodium deoxycholate. After sodium deoxycholate perfusion, the active tone of the preparation was produced by perfusion with Krebs solution containing methoxamine (2 mM). After confirming successful removal of the endothelium by the lack of a relaxant effect after 1 nmol acetylcholine injection, a-methylhistamine perfusions were performed.
In another series of experiments, the vascular responses to a-methylhistamine in preparations with intact endothelium were examined in the presence of a NO synthase inhibitor, N w -nitro-L-arginine methyl ester (L-NAME, 100 mM, Sigma Aldrich), a cyclooxygenase inhibitor, indomethacin (1 mM, Sigma Aldrich), high KCl (30 mM, Wako Pure Chemical Ind., Ltd., Osaka, Japan) or a nonselective K ϩ -channel blocker, tetraethylammonium (5 mM, Sigma Aldrich). Krebs solution containing methoxamine (2-7 mM), each inhibitor and amethylhistamine at a concentration was perfused for 1 min. The concentration of each inhibitor was employed according to previous reports described by Jin H. et al. 26) and Jin X. et al. 18) At the end of each experiment, the preparation was perfused with 100 mM papaverine (Dainippon-Sumitomo Pharmaceutical, Osaka, Japan) to cause complete relaxation. Vasodilator activity was expressed as a percentage of the perfusion pressure at maximum relaxation induced by papaverine.
All drugs, except sodium deoxycholate, were dissolved in distilled water and diluted with Krebs solution containing 2-7 mM methoxamine, then perfused or injected directly. Sodium deoxycholate was dissolved in 0.9% saline.
Statistical Analysis Data are presented as the meanϮ S.E.M. Statistical analysis was performed using Student's unpaired between two groups and one-way analysis of variance followed by Tukey's test among multiple groups. A value of pϽ0.05 was considered statistically significant.
RESULTS

Vasodilator Responses Induced by Perfusion of a aMethylhistamine
In the perfused mesenteric vascular bed with intact endothelium contracted by 7 mM methoxamine, a bolus injection of acetylcholine caused a sharp decrease in perfusion pressure due to vasodilation (Fig. 1A) . The vasodilator response to acetylcholine has been shown to be endothelium-dependent and mediated by EDRFs including endothelial NO, prostanoids and endothelial-derived hyperpolarizing factors (EDHFs). 18, [27] [28] [29] As shown in Fig. 1A and Fig. 2 , perfusion of a-methylhistamine for 1 min at concentrations of 1 to 100 mM produced a concentration-dependent decrease in perfusion pressure due to vasodilation. The a-methylhistamine-induced vasodilation was transient and disappeared within 5 min. The maximum response induced by the highest concentration (100 mM) of a-methylhistamine was 44.6Ϯ6.8% (Fig. 2) .
Effects of Endothelium Removal on the a a-Methylhistamine-Induced Vasodilator Responses Treatment of the perfused mesenteric vascular bed with sodium deoxycholate abolished the acetylcholine-induced vasodilation, indicating that the response was endothelium-dependent and confirmed successful removal of the endothelium (Fig. 1B) . In this preparation, a-methylhistamine did not induce the concentration-dependent vasodilation (Fig. 1B, Fig. 2) .
Effects of Thioperamide or Clobenpropit on the a a-
Methylhistamine-Induced Vasodilator Responses
In the preparations with intact endothelium, vasodilation in response to a-methylhistamine at concentrations of 1 to 30 mM was abolished in the presence of the histamine H 3 receptor antagonist, thioperamide (1 mM) or clobenpropit (1 mM) (Fig.  3) . Each antagonist significantly inhibited, but did not abolish, the response to the highest concentration (100 mM), as shown in Fig. 3 . Effects of Chlorpheniramine and Cimetidine on the a a-Methylhistamine-Induced Vasodilator Responses As shown in Fig. 4 , in the preparation with intact endothelium, the histamine H 1 receptor antagonist chlorpheniramine (1 mM) significantly inhibited vasodilator response to amethylhistamine at the highest concentration of 100 mM, but not low and moderate concentrations of 1 to 30 mM. However, the histamine H 2 receptor antagonist cimetidine (1 mM) did not affect the a-methylhistamine-induced vasodilation at any concentrations. Effects of L-NAME and Indomethacin on the a aMethylhistamine-Induced Vasodilator Responses In preparations with intact endothelium, L-NAME (100 mM) or indomethacin (1 mM) significantly attenuated, but did not abolish, the vasodilation in response to a-methylhistamine (Fig. 5) . Combined perfusion of L-NAME (100 mM) and indomethacin (1 mM) abolished the a-methylhistamine-induced vasodilation (Fig. 5) .
Effect of High KCl and Tetraethylammonium on the a a-Methylhistamine-Induced Vasodilator Responses
In preparations with intact endothelium, high KCl (30 mM) almost abolished vasodilation in response to perfusion of amethylhistamine (Fig. 6) . The nonselective K ϩ -channel inhibitor tetraethylammonium (5 mM) significantly attenuated, but did not abolish, the a-methylhistamine-induced vasodilation (Fig. 6) .
DISCUSSION
The present study demonstrated that perfusion of amethylhistamine, a selective histamine H 3 receptor agonist, produced concentration-dependent vasodilator responses in the rat mesenteric resistance artery. The a-methylhistamineinduced vasodilation was eliminated by endothelium removal, indicating that the vasodilation is endothelium-dependent. Furthermore, the histamine H 3 receptor antagonists thioperamide and clobenpropit, significantly inhibited the amethylhistamine-induced vasodilation. In contrast, the histamine H 2 receptor antagonist, cimetidine, had no effect on the vasodilator responses to a-methylhistamine at any concentrations. Additionally, the histamine H 1 receptor antagonist chlorpheniramine did not inhibit vasodilation induced by amethylhistamine at concentrations less than 30 mM, suggesting that chlorpheniramine has no effect on histamine H 3 -receptors.
Histamine H 3 receptor subtypes have been shown in neuronal terminals, both in the brain and in peripheral tissues. 1, 3, 30) Histamine H 3 receptor-mediated vasodilation has also been reported in the endothelium-dependent rabbit mid- dle cerebral artery, 19, 20) the hindlimb vascular bed 22) and the mesenteric vascular bed of the cat. 23) Taken together, the present findings suggest that a-methylhistamine induces endothelium-dependent vasodilation, which is mediated by histamine H 3 receptors located on the endothelium of the rat mesenteric resistance artery. However, since the histamine H 1 receptor antagonist significantly inhibited the response to the highest concentration of a-methylhistamine, a-methylhistamine at higher concentrations of more than 100 mM has histamine H 1 receptor-agonistic activity. Similar results have been reported by Hegde et al. 14) regarding a-methylhistamine. It is widely accepted that the endothelium at the luminal surface of blood vessels is an important regulator of vascular tone via release of various endothelium-derived endogenous substances. 27, 31) Endothelial cells release different kinds of EDRFs 15, 16) including NO, PGI 2 and EDHFs. Vasodilator responses to a-methylhistamine have been reported to be mediated by NO and PGI 2 release in the isolated cerebral artery of the rabbit, 19, 20) the aorta of the rat, 21 ) the hindlimb vascular bed 22) and the mesenteric vascular bed of the cat. 23) Additionally, involvement of EDHFs in a-methylhistamine-induced vasodilation, which is associated with activation of the K ϩ -channel, has been shown in the hindlimb vascular bed of the cat.
22)
The present study demonstrated that vasodilator responses to a-methylhistamine were markedly attenuated by the NO synthase inhibitor L-NAME, suggesting that the release of NO from the endothelium plays a significant role in mediating vasodilator responses to this histamine H 3 receptor-selective agonist in the endothelium. These findings are in line with the observations of other reports. 20, 23) Additionally, the present study showed that indomethacin caused partial inhibition of vasodilator responses to a-methylhistamine, which was smaller than that of L-NAME, implicating that a-methylhistamine induces the release of relaxing factors, probably PGI 2 , a metabolite of arachidonic acid, via cyclooxygenase in the endothelium of the rat mesenteric resistance artery. A similar finding has been reported by Ea Kim et al. 19, 20) In their reports, the H 3 receptors have been shown to relax rabbit middle cerebral artery via an endothelium-dependent mechanism involving both nitric oxide and prostanoid release. However, simultaneous treatment with L-NAME and indomethacin in the vascular mesenteric bed with an intact endothelium did not abolish the a-methylhistamine-induced endothelium-dependent vasodilation. Therefore, it is likely that other endothelium-derived relaxing factors besides NO and PGI 2 are involved in the histamine H 3 receptor-mediated vasodilation.
Evidence has accumulated that NO and PGI 2 of EDRFs play a prominent role in the tone control of large conduit arteries, whereas EDHFs plays a major role in the small resistance arteries in response to vasoactive substances or physical stimuli. 28, 32, 33) EDHFs, which has been described as an endothelium-derived non-NO and non-PGI 2 factor, induces hyperpolarization of vascular smooth muscle cells by opening K ϩ channels. 15, 34, 35) Jin et al. 18) reported that endothelium-dependent vasodilation in response to acetylcholine and Ca 2ϩ -ionophore (A23187) in the rat mesenteric vascular bed was not inhibited by L-NAME and indomethacin, but was blunted by K ϩ -channel inhibition by high KCl and tetraethylammonium. Therefore, it is very likely that EDHFs is mainly responsible for the endothelium-dependent vasodilation in the rat mesenteric vascular bed, which is composed of many resistance arteries. Jin et al. 26) demonstrated that histamine induces histamine H 1 receptor-mediated endothelium-dependent vasodilation and histamine H 2 receptor-mediated endothelium-independent vasodilation in the rat mesenteric vascular bed. Additionally, this report showed that the histamine-induced endothelium-dependent vasodilation was resistant to L-NAME and indomethacin, suggesting that EDHFs are responsible for histamine H 1 receptor-mediated vasodilation. However, in the present study, the a-methylhistamine-induced endothelium-dependent vasodilation was markedly attenuated by elimination of NO and PGI 2 . Therefore, stimulation of histamine H 3 receptors on the endothelium of the rat mesenteric arteries releases EDRFs, including NO and PGI 2 , while activation of histamine H 1 receptors and muscarinic acetylcholine receptors releases mainly EDHFs. The histamine H 3 receptor-mediated vasodilator response in the rat mesenteric arteries is smaller than that of the vasodilator response mediated by histamine H 1 receptors or muscarinic acetylcholine receptors. The weak potency of the histamine H 3 receptor-mediated response seems to be due to a lower activity of EDHFs release in the mesenteric artery.
In the present study, the a-methylhistamine-induced endothelium-dependent vasodilation was significantly inhibited, but not abolished, by a nonselective K ϩ -channel blocker, tetraethylammonium, suggesting that EDHFs are involved in the vasodilation. However, this seems to be mainly due to a histamine H 1 receptor-mediated response, since a-methylhistamine has only weak histamine H 1 receptor agonistic action. In contrast, nonselective K ϩ -channel blockade by a 30 mM high KCl medium abolished the a-methylhistamine-induced vasodilation. These findings suggest that the a-methylhistamine-induced endothelium-dependent vasodilation is an EDHFs-mediated response, which is associated with activation of K ϩ -channel involvement and is in agreement with the report of Champion and Kadowitz. 22) However, it seems likely that abolishment of the a-methylhistamine-induced response under high KCl conditions, which induce cell membrane depolarization, may result from blockade of EDRFs release.
In conclusion, the present findings suggest that a-methylhistamine induces endothelium-dependent vasodilation via histamine H 3 receptors on the vascular endothelium of the rat mesenteric resistance artery. It is also suggested that histamine H 3 receptor-mediated vasodilator effects are mainly mediated by NO of EDRFs and partially by PGI 2 and EDHFs.
